Please use this identifier to cite or link to this item:
Title: Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years
Authors: Chan, M.Y. 
Sun, J.-L.
Newby, L.K.
Lokhnygina, Y.
White, H.D.
Moliterno, D.J.
Théroux, P.
Ohman, E.M.
Simoons, M.L.
Mahaffey, K.W.
Pieper, K.S.
Giugliano, R.P.
Armstrong, P.W.
Califf, R.M.
Van De Werf, F.
Harrington, R.A.
Keywords: Antithrombotic therapy
Non-ST-segment elevation acute coronary syndromes
Randomized clinical trials
Issue Date: 31-Jul-2013
Citation: Chan, M.Y., Sun, J.-L., Newby, L.K., Lokhnygina, Y., White, H.D., Moliterno, D.J., Théroux, P., Ohman, E.M., Simoons, M.L., Mahaffey, K.W., Pieper, K.S., Giugliano, R.P., Armstrong, P.W., Califf, R.M., Van De Werf, F., Harrington, R.A. (2013-07-31). Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. International Journal of Cardiology 167 (2) : 548-554. ScholarBank@NUS Repository.
Abstract: Background: Data are limited on whether clinical trials have randomized higher-risk patients over time and how trends in risk profiles and evidence-based pharmacotherapies have influenced trial outcomes. We quantified changes in baseline risk, treatment, and outcomes of patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS) randomized in 9 phase 3 clinical trials of antithrombotic therapy over 15 years. Methods: We studied 58,771 patients in GUSTO IIb, PURSUIT, PARAGON-A, PARAGON-B, PRISM, PRISM-PLUS, GUSTO IV-ACS, SYNERGY, and EARLY ACS. Patient-level data were mapped to 3 pre-specified 5-year randomization periods. Temporal trends in GRACE score-predicted mortality were compared with trends in observed mortality. Results: Over time, in-hospital and discharge use of thienopyridines (p = 0.001), statins (p < 0.0001), and angiotensin-converting enzyme inhibitors (p < 0.0001) increased, and hospital length-of-stay decreased (p = 0.024). Blood transfusion use increased (8.3% [1994-98], 10.7% [1999-2003], 13% [2004-08], p = 0.0002) despite stable rates of severe bleeding (0.9% [1994-98], 1.4% [1999-2003] and 1.1% [2004-08], p = 0.127) and coronary artery bypass grafting (12.4% [1994-98], 13.7% [1999-2003] 13.1% [2004-08], p = 0.880). Although predicted 6-month mortality increased (6.9% [1994-98], 9.0% [1999-2003], 7.9% [2004-08], p = 0.017), observed 6-month mortality decreased (6.7% [1994-98], 5.8% [1999-2003], 5.1% [2004-08], p = 0.025). Thirty-day myocardial infarction rates remained stable (9.2% [1994-98], 9.3% [1999-2003], 10% [2004-08], p = 0.539). Conclusions: Despite enrolling higher-risk patients into these NSTE ACS trials, with better treatment, observed mortality declined over the past 15 years. The appropriateness of increased blood transfusion despite unchanged bleeding rates deserves further study. © 2013 Elsevier Ireland Ltd. All rights reserved.
Source Title: International Journal of Cardiology
ISSN: 01675273
DOI: 10.1016/j.ijcard.2012.01.065
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Oct 15, 2021


checked on Oct 15, 2021

Page view(s)

checked on Oct 14, 2021

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.